Skip to content
Baret News – Lifestyle
Author:
ELI LILLY AND COMPANY
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
June 25, 2026
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
June 24, 2026
Lilly declares third-quarter 2026 dividend
June 22, 2026
Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
June 14, 2026
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
June 13, 2026
FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
June 9, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
June 2, 2026
Lilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
May 31, 2026
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
1
2
3
Next Page
→